Health Economics›Acquired thrombotic thrombocytopenic purpura›Initial therapy

Initial therapy

Acquired thrombotic thrombocytopenic purpura · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Plasma exchange N/A - secondary systemic drug	—	R 0	—	—	—	—	—	—
Caplacizumab monotherapy Partial	—	—	—	—	—	—	—	—
Caplacizumab and Plasma exchange N/A - secondary systemic drug Partial	—	—	—	—	—	—	—	—

3 of 3 regimens shown